Tapentadol placed in schedule II in the US and filed in the EU
This article was originally published in Scrip
Johnson & Johnson's centrally acting analgesic tapentadol is to be placed in schedule II of the Controlled Substances Act in the US, the Drug Enforcement Administration has concluded in a final rule.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.